A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Capital Federal, Buenos Aires 1426, Argentina
Ostrava-Poruba, 708 52, Czechia
Sunto-gun, Shizuoka 4118777, Japan
Chuo-ku, Tokyo 1040045, Japan
Chuo-shi, Yamanashi 4093898, Japan
Romania, 400015, Romania
Saxonwold, Johannesburg, Gauteng 2196, South Africa
Songpa-gu, Seoul 05505, South Korea
Gothenberg, 413 45, Sweden
Surrey, SM2 5PT, United Kingdom